Advertisement

Neurocritical Care

, Volume 29, Issue 3, pp 491–495 | Cite as

Safety and Efficiency of Intravenous Push Lacosamide Administration

  • K. Erin Davidson
  • Joshua Newell
  • Khalid Alsherbini
  • Joseph Krushinski
  • G. Morgan Jones
Original Article

Abstract

Background/objective

Intravenous (IV) lacosamide use for status epilepticus has increased in recent years and is recommended for refractory status epilepticus by current guidelines. Per the lacosamide package labeling, the preferred route of administration is diluted and infused over 30–60 min; however, administration undiluted is also acceptable and recent literature demonstrated safety at a maximum rate of 80 mg per minute (Kellinghaus et al. in Acta Neurol Scand 123:137–141, 2011). Undiluted administration as an IV push has potential to increase efficiency of administration to patients needing urgent seizure control since it may be dispensed from automatic dispensing cabinets in patient care areas. This study aims to compare safety outcomes and efficiency of administration in patients receiving lacosamide IV push compared to IV piggyback.

Methods

We present a single-center, retrospective cohort study of patients receiving lacosamide via IV piggyback or IV push from June 2016 to July 2017. Baseline characteristics, data related to potential safety concerns and timing of ordering, verification, and administration were collected. The primary safety outcomes were incidence of infusion site reactions, hypotension (systolic blood pressure [SBP] < 90 mm Hg), and bradycardia (heart rate [HR] < 50 beats per minute) documented within 2 h of each lacosamide dose. Secondary safety outcomes included the incidence of PR interval prolongation in patients with at least one electrocardiogram measured. The primary efficiency outcome was the time between order verification and administration.

Results

Patients in the IV piggyback (n = 88) and IV push (n = 78) groups had similar baseline characteristics, initial dose, SBP, and HR. Hypotension (8 vs. 10.3%) and bradycardia (2.3 vs. 2.6%) rates were similar among both groups (p > 0.05). Only one patient in each group had documented PR prolongation, and no documented infusion reactions occurred. Median time from order verification to administration was significantly reduced in the IV push group (35 min vs. 1 h 49 min; p < 0.001).

Conclusions

Administration of lacosamide via IV push results in similar adverse effect rates to IV piggyback preparations with more efficient time to administration.

Keywords

Seizures Epilepsy Neurology Efficiency 

Notes

Author Contributions

KED is responsible for design of the study, acquisition, analysis and interpretation of data as well as drafting, revising, and final manuscript approval; JN, responsible for acquisition of data and final manuscript approval; KAA, responsible for conceptual design of the work and final manuscript approval; JK, responsible for conceptual design and implementation of the work, revising, and final manuscript approval; and GMJ, responsible for conceptual design of study, analysis and interpretation of data, as well as drafting, revising, and final manuscript approval.

Source of Support

No funds were used for the completion of this research.

Compliance with Ethical Standards

Conflict of interest

All authors declare that they have no conflict of interest to disclose.

Ethical Approval

All data were extracted from the electronic medical record, and the study was approved by the University of Tennessee Institutional Review Board.

References

  1. 1.
    Kellinghaus C, Berning S, Immisch I, et al. Intravenous lacosamide for treatment of status epilepticus. Acta Neurol Scand. 2011;123:137–41.CrossRefPubMedPubMedCentralGoogle Scholar
  2. 2.
    Brophy GM, Bell R, Claassen J, et al. Guidelines for the evaluation and management of status epilepticus. Neurocrit Care. 2012;17:3–23.CrossRefPubMedCentralGoogle Scholar
  3. 3.
    Vimpat (lacosamide) [prescribing information]. Smyrna, GA: ICB Inc; 2017.Google Scholar
  4. 4.
    Misra UK, Dubey D, Kalita J. Comparison of lacosamide versus sodium valproate in status epilepticus: a pilot study. Epilepsy Behav. 2017;76:110–3.CrossRefPubMedPubMedCentralGoogle Scholar
  5. 5.
    Newey CR, Le NM, Ahrens C, Sahota P, Hantus S. The Safety and effectiveness of intravenous lacosamide for refractory status epilepticus in the critically ill. Neurocrit Care. 2017;26:273–9.CrossRefPubMedGoogle Scholar
  6. 6.
    Goodwin H, Hinson HE, Shermock KM, Karanjia N, Lewin JJ 3rd. The use of lacosamide in refractory status epilepticus. Neurocrit Care. 2011;14:348–53.CrossRefPubMedGoogle Scholar
  7. 7.
    Hofler J, Unterberger I, Dobesberger J, Kuchukhidze G, Walser G, Trinka E. Intravenous lacosamide in status epilepticus and seizure clusters. Epilepsia. 2011;52:e148–52.CrossRefPubMedGoogle Scholar
  8. 8.
    Krause LU, Brodowski KO, Kellinghaus C. Atrioventricular block following lacosamide intoxication. Epilepsy Behav. 2011;20:725–7.CrossRefPubMedPubMedCentralGoogle Scholar
  9. 9.
    Kellinghaus C, Berning S, Besselmann M. Intravenous lacosamide as successful treatment for nonconvulsive status epilepticus after failure of first-line therapy. Epilepsy Behav. 2009;14:429–31.CrossRefPubMedPubMedCentralGoogle Scholar
  10. 10.
    Small-volume parenteral solutions shortages. American Society of Health System Pharmacists. 2017. http://www.ashp.org/Drug-Shortages/Shortage-Resources/Publications/Small-Volume-Parenteral-Solutions-Shortages. Accessed 16 Jan 2018.
  11. 11.
    Safe practice guidelines for adult IV push medications. ISMP. 2015. http://www.ismp.org/Tools/guidelines/IVSummitPush/IVPushMedGuidelines.pdf. Accessed 16 Jan 2018.

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature and Neurocritical Care Society 2018

Authors and Affiliations

  • K. Erin Davidson
    • 1
  • Joshua Newell
    • 2
  • Khalid Alsherbini
    • 1
    • 3
  • Joseph Krushinski
    • 1
  • G. Morgan Jones
    • 1
    • 2
    • 3
  1. 1.Methodist University HospitalMemphisUSA
  2. 2.Department of Clinical Pharmacy and Translational ScienceUniversity of Tennessee Health Sciences CenterMemphisUSA
  3. 3.Department of Neurology and NeurosurgeryUniversity of Tennessee Health Sciences CenterMemphisUSA

Personalised recommendations